Determination That NAMENDA (Memantine Hydrochloride) Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
FDA determined that NAMENDA (memantine hydrochloride) tablets, 5 mg and 10 mg, were not withdrawn from sale for reasons of safety or effectiveness, which may affect the market for generic versions.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on September 1, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) facilities involved with memantine hydrochloride tablets. should confirm how it applies to their specific situation before acting. There is a time constraint attached: No specific deadline provided.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA officially determined that NAMENDA tablets were not withdrawn for safety or effectiveness reasons, which may clarify regulatory status and affect generic competition.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) facilities involved with memantine hydrochloride tablets.
What you must do
Review the determination and assess any impact on existing ANDAs or marketing plans for memantine hydrochloride tablets.
Deadline
No specific deadline provided.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- What to Know About the FDA’s Recent Decision to Allow Florida to Import Prescription Drugs from Canada - kff.org
- FDA Warns Exosome Maker for Marketing Outside Its IND - medpagetoday.com
- FDA Proposes CGMP Framework for Animal Drug Compounding - Lab Manager
- GLP‑1 Compliance- FDA Targets Telehealth Marketing in 30 New Warning Letters - natlawreview.com
- Court bans Florida compounder from all manufacturing until it can meet FDA requirements - fiercepharma.com